Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche Introduces New GS FLX+ Software

Published: Thursday, November 08, 2012
Last Updated: Thursday, November 08, 2012
Bookmark and Share
First high-throughput sequencing platform to deliver one million reads with read lengths of up to 1000 bp and beyond.

Roche has announced the launch and immediate availability of a new software package (v2.8) that significantly improves long-read shotgun sequencing performance on its GS FLX+ System.

This system is the first high-throughput sequencing platform to deliver one million reads with accuracy and length that are comparable to traditional Sanger-based methods.

The improvements will allow researchers to discover more novel complex genetic variants and uncover the hidden biology in difficult-to-sequence regions of genomes, transcriptomes, and metagenomic samples.

The GS FLX+ System and software will be presented at the American Society for Human Genetics Annual Meeting in San Francisco.

“This latest software release represents a major step forward in meeting the expectations of our customers on the long-read performance of the GS FLX+ System,” said Thomas Schinecker, President Roche Sequencing Solutions.

Schinecker continued, “Over 30 leading sequencing laboratories around the world are already implementing the latest improvements of our new software, and their feedback has been overwhelmingly positive.”

Since the launch of the GS FLX+ System, researchers have confirmed the value of extra-long reads for more complete de novo assembly of whole genomes, superior full-length transcriptome analysis, and better characterization of mixed metagenomic samples.

The latest software will further improve the sequencing results for these applications and also bring new functionality enhancements to the suite of 454 Sequencing System’s bioinformatics tools for de novo assembly, mapping, and variant analysis.

“We have experienced excellent results in our laboratory using the latest GS FLX+ software. All sequencing metrics, including read length, have exceeded our expectations,” explained Hiroshi Tarui, RIKEN Omics Science Center and Yokohama City University KIHARA Institute for Biological Research.

Tarui continued, “We are excited to use the platform in our de novo transcriptome studies, where the long reads are critical for full-length assembly of cDNA transcripts and splice variant investigation.”

“We have been using the GS FLX+ System extensively for our de novo sequencing project of different tobacco strains achieving modal read lengths of around 820 bases and several runs with an output of more than 1 Gb,” said Bernd Timmermann, Head of the Max Planck Institute Sequencing Core Facility, Berlin, Germany.

Timmermann continued, “With the upgrade to the v2.8 software, we are seeing an improvement in average and modal read length in all cases. We will continue to use our GS FLX+ Systems in the future for our de novo sequencing and metagenome projects.”

Roche also plans to roll out long-read improvements for long amplicon sequencing on the GS FLX+ System. They will advance sequencing results for targeted sequencing and 16S/18S rRNA metagenomic applications.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Blueprint Medicine, Roche Collaborate
Collaboration combines blueprint medicines' proprietary drug discovery platform and immunokinase expertise with Roche's cancer immunotherapy expertise.
Wednesday, March 16, 2016
Roche to Acquire Seragon Pharmaceuticals
Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer.
Wednesday, July 02, 2014
Roche Recieves FDA Approval for Cervical Cancer Screening HPV Test
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older.
Friday, April 25, 2014
FDA Recommends Roche's HPV Test as Primary Screening Tool
Test will assess risk of cervical cancer of women 25 years and older.
Thursday, March 13, 2014
Roche's Troponin T Nominated for International Inventor Award
European Patent Office nominates the team of Klaus Hallermayer from Roche Penzberg, jointly with Prof. Hugo Katus from the University of Heidelberg.
Monday, June 11, 2012
New Findings in Drug-Induced Receptor Activity
The discovery that drugs targeting a single GPCR can differentially modulate distinct subsets of the receptor signaling repertoire is a very important step in drug discovery.
Wednesday, February 15, 2012
Ghent University will Use Roche's LightCycler® 1536 Instrument in the Field of HT PCR for Cancer Research
Roche and Ghent University enter agreement for the use of Roche's LightCycler® 1536 Instrument in various cancer research projects in Ghent.
Thursday, April 22, 2010
Roche and High Throughput Genomics Partner for Advanced Gene Expression Analysis Solution
Roche NimbleGen will provide HTG with high density, multiplex DNA microarray slides for advanced gene expression analysis.
Monday, November 09, 2009
Real-time and Dynamic Monitoring of Virus-mediated Cytopathogenicity with Roche’s xCELLigence System
Göttingen University study utilizes xCELLigence system from Roche Applied Science for testing of virus-mediated cytopathogenicity.
Friday, May 01, 2009
Roche Nimblegen and Biogemma to Develop Sequence Capture Technology for High-Throughput Sequencing of Crop Genomes
The partnership will facilitate marker-assisted breeding programs to select the crops with desirable traits that will benefit human lives.
Tuesday, January 13, 2009
Synta and Roche Form Discovery, Development, and Commercialization Alliance in Inflammation
The alliance aims to develop new category of oral agents for the potential treatment of rheumatoid arthritis and other inflammatory diseases.
Monday, January 12, 2009
Roche Applied Science Introduces new xCELLigence RTCA MP Instrument
The xCELLigence RTCA MP allows high throughput online-measurement of cell activities without labeling.
Friday, December 05, 2008
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!